Current Edition

Green light for UK trial of nasal coronavirus vaccine

Open Orphan and Codagenix have received approval from the UK’s independent Medicines and Healthcare Products Regulatory Agency (MHRA) to conduct a Phase I study of its COVID-19 vaccine.

The study will assess the safety and immunogenicity of a single-dose nasal vaccine candidate COVI-VAC in 48 healthy young adult volunteers.

COVI-VAC uses the entire virus in a weakened form, and so has the potential to induce broad antibody, cellular and mucosal immunity with a single intra-nasal dose.

According to Open Orphan, it could be one of the first vaccines to provide long-term immunity from COVID-19.

“We believe COVI-VAC, a needle-free, single dose vaccine, is well-suited to address potential gaps in supplying the global community, as there is likely to be significant unmet need even after the initial roll-out of first generation COVID-19 vaccines,” added Sybil Tasker, Codagenix’ chief medical officer.

The study is expected to begin next month, with first data read outs expected in early Q2 2020.